TY  - JOUR
AU  - Ibrić, Svetlana
AU  - Parojčić, Jelena
AU  - Mrhar, Ales
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2814
PB  - Elsevier Science BV, Amsterdam
T2  - International Journal of Pharmaceutics
T1  - From smart materials to advanced drug delivery systems Preface
VL  - 533
IS  - 2
SP  - 323
EP  - 323
DO  - 10.1016/j.ijpharm.2017.08.105
ER  - 

@article{
author = "Ibrić, Svetlana and Parojčić, Jelena and Mrhar, Ales",
year = "2017",
publisher = "Elsevier Science BV, Amsterdam",
journal = "International Journal of Pharmaceutics",
title = "From smart materials to advanced drug delivery systems Preface",
volume = "533",
number = "2",
pages = "323-323",
doi = "10.1016/j.ijpharm.2017.08.105"
}

Ibrić, S., Parojčić, J.,& Mrhar, A.. (2017). From smart materials to advanced drug delivery systems Preface. in International Journal of Pharmaceutics
Elsevier Science BV, Amsterdam., 533(2), 323-323.
https://doi.org/10.1016/j.ijpharm.2017.08.105

Ibrić S, Parojčić J, Mrhar A. From smart materials to advanced drug delivery systems Preface. in International Journal of Pharmaceutics. 2017;533(2):323-323.
doi:10.1016/j.ijpharm.2017.08.105 .

Ibrić, Svetlana, Parojčić, Jelena, Mrhar, Ales, "From smart materials to advanced drug delivery systems Preface" in International Journal of Pharmaceutics, 533, no. 2 (2017):323-323,
https://doi.org/10.1016/j.ijpharm.2017.08.105 . .

TY  - CONF
AU  - Vovk, Tomaz
AU  - Grabnar, Iztok
AU  - Kos, M. Kerec
AU  - Jakovljević, M. B.
AU  - Vučićević, Katarina
AU  - Mrhar, Ales
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1265
PB  - Elsevier Science BV, Amsterdam
C3  - European Journal of Pharmaceutical Sciences
T1  - The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics
VL  - 38
IS  - 1
SP  - 51
EP  - 52
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1265
ER  - 

@conference{
author = "Vovk, Tomaz and Grabnar, Iztok and Kos, M. Kerec and Jakovljević, M. B. and Vučićević, Katarina and Mrhar, Ales",
year = "2009",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics",
volume = "38",
number = "1",
pages = "51-52",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1265"
}

Vovk, T., Grabnar, I., Kos, M. K., Jakovljević, M. B., Vučićević, K.,& Mrhar, A.. (2009). The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 38(1), 51-52.
https://hdl.handle.net/21.15107/rcub_farfar_1265

Vovk T, Grabnar I, Kos MK, Jakovljević MB, Vučićević K, Mrhar A. The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics. in European Journal of Pharmaceutical Sciences. 2009;38(1):51-52.
https://hdl.handle.net/21.15107/rcub_farfar_1265 .

Vovk, Tomaz, Grabnar, Iztok, Kos, M. Kerec, Jakovljević, M. B., Vučićević, Katarina, Mrhar, Ales, "The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics" in European Journal of Pharmaceutical Sciences, 38, no. 1 (2009):51-52,
https://hdl.handle.net/21.15107/rcub_farfar_1265 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1240
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - No effect of gender on carbamazepine elimination-population approach
VL  - 31
IS  - 1
SP  - 118
EP  - 119
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1240
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Veličković, Ružica and Mrhar, Ales and Grabnar, Iztok",
year = "2009",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "No effect of gender on carbamazepine elimination-population approach",
volume = "31",
number = "1",
pages = "118-119",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1240"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R., Mrhar, A.,& Grabnar, I.. (2009). No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science
Springer, Dordrecht., 31(1), 118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Mrhar A, Grabnar I. No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science. 2009;31(1):118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Veličković, Ružica, Mrhar, Ales, Grabnar, Iztok, "No effect of gender on carbamazepine elimination-population approach" in Pharmacy World & Science, 31, no. 1 (2009):118-119,
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1109
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study
VL  - 30
IS  - 5
SP  - 673
EP  - 674
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1109
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2008",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study",
volume = "30",
number = "5",
pages = "673-674",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1109"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2008). Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science
Springer, Dordrecht., 30(5), 673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Mrhar A, Grabnar I. Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science. 2008;30(5):673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study" in Pharmacy World & Science, 30, no. 5 (2008):673-674,
https://hdl.handle.net/21.15107/rcub_farfar_1109 .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Milijković, Branislava
AU  - Veličković, Ružica
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/898
AB  - The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Therapeutic Drug Monitoring
T1  - Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data
VL  - 29
IS  - 6
SP  - 781
EP  - 788
UR  - https://hdl.handle.net/21.15107/rcub_farfar_898
ER  - 

@article{
author = "Vučićević, Katarina and Milijković, Branislava and Veličković, Ružica and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2007",
abstract = "The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Therapeutic Drug Monitoring",
title = "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data",
volume = "29",
number = "6",
pages = "781-788",
url = "https://hdl.handle.net/21.15107/rcub_farfar_898"
}

Vučićević, K., Milijković, B., Veličković, R., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2007). Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring
Lippincott Williams & Wilkins, Philadelphia., 29(6), 781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898

Vučićević K, Milijković B, Veličković R, Pokrajac M, Mrhar A, Grabnar I. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring. 2007;29(6):781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898 .

Vučićević, Katarina, Milijković, Branislava, Veličković, Ružica, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data" in Therapeutic Drug Monitoring, 29, no. 6 (2007):781-788,
https://hdl.handle.net/21.15107/rcub_farfar_898 .